Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18 -34.9%	$0.41	$0.07 ▼ $5.92	$2.92M	2.07	4.48 million shs	22.99 million shs
NERV Minerva Neurosciences	$1.82 +1.1%	$1.67	$1.15 ▼ $3.50	$12.59M	-0.37	23,087 shs	2,386 shs
REVB Revelation Biosciences	$0.84 -3.6%	$2.06	$0.74 ▼ $56.00	$840K	-0.09	362,304 shs	542,074 shs
RLYB Rallybio	$0.35 -5.3%	$0.32	$0.22 ▼ $1.54	$15.40M	-1.24	123,725 shs	152,388 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	-78.09%	-96.94%
NERV Minerva Neurosciences	+2.60%	-1.30%	+24.38%	-2.63%	-44.12%
REVB Revelation Biosciences	+12.40%	+10.13%	-64.20%	-69.26%	-97.73%
RLYB Rallybio	+18.63%	+9.47%	+12.36%	-41.95%	-75.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	2.7215 of 5 stars	4.0	0.0	4.3	0.0	0.0	1.3
NERV Minerva Neurosciences	3.5186 of 5 stars	3.0	3.0	4.6	0.0	0.0	1.3
REVB Revelation Biosciences	0.2572 of 5 stars	0.0	2.0	0.0	0.6	0.0	1.3
RLYB Rallybio	2.5564 of 5 stars	3.0	5.0	0.0	0.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.00	Hold	$3.62	1,895.87% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	174.73% Upside
REVB Revelation Biosciences	0.00	N/A	N/A	N/A
RLYB Rallybio	2.00	Hold	$10.00	2,753.07% Upside

Current Analyst Ratings Breakdown

Latest REVB, AFMD, NERV, and RLYB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	AFMD Affimed	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	AFMD Affimed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/13/2025	AFMD Affimed	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	AFMD Affimed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$11.00 ➝ $0.10
5/13/2025	AFMD Affimed	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$5.00 ➝ $0.39
4/15/2025	RLYB Rallybio	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/13/2025	RLYB Rallybio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	RLYB Rallybio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
4/8/2025	RLYB Rallybio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
NERV Minerva Neurosciences	N/A	N/A	$0.21 per share	8.62	($3.67) per share	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$9.02 per share	N/A
RLYB Rallybio	$640K	22.79	N/A	N/A	$1.49 per share	0.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	9/1/2025 (Estimated)
NERV Minerva Neurosciences	$1.44M	$0.82	2.22	N/A	N/A	N/A	-20.68%	15.73%	8/5/2025 (Estimated)
REVB Revelation Biosciences	-$15.04M	-$102.61	N/A	N/A	N/A	N/A	-299.46%	-115.36%	8/8/2025 (Estimated)
RLYB Rallybio	-$57.78M	-$1.09	N/A	N/A	N/A	-5,682.19%	-72.31%	-64.78%	8/14/2025 (Estimated)

Latest REVB, AFMD, NERV, and RLYB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	-$0.50	+$0.57	-$0.50	N/A	N/A
5/8/2025	Q1 2025	REVB Revelation Biosciences	-$6.88	-$2.11	+$4.77	-$2.11	N/A	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
NERV Minerva Neurosciences	N/A	9.21	9.21
REVB Revelation Biosciences	N/A	3.60	3.60
RLYB Rallybio	N/A	14.68	14.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
NERV Minerva Neurosciences	34.56%
REVB Revelation Biosciences	12.80%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
NERV Minerva Neurosciences	8.60%
REVB Revelation Biosciences	2.30%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
NERV Minerva Neurosciences	9	6.99 million	6.39 million	Not Optionable
REVB Revelation Biosciences	10	960,000	942,000	Not Optionable
RLYB Rallybio	40	41.61 million	37.99 million	Not Optionable

REVB, AFMD, NERV, and RLYB Headlines

Recent News About These Companies

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

June 13, 2025 | finance.yahoo.com

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 11, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Rallybio Stock Short Interest Report | NASDAQ:RLYB | Benzinga

April 9, 2025 | benzinga.com

Rallybio discontinues RLYB212 program

April 9, 2025 | markets.businessinsider.com

Rallybio sinks as it drops RLYB212 for prevention of FNAIT

April 9, 2025 | thepharmaletter.comT

HC Wainwright & Co. Downgrades Rallybio (RLYB)

April 9, 2025 | msn.com

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

April 9, 2025 | zacks.com

Citizens JMP downgrades Rallybio on RLYB212 discontinuation

April 9, 2025 | markets.businessinsider.com

JMP Securities downgrades Rallybio (RLYB) to a Hold

April 9, 2025 | theglobeandmail.com

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

April 8, 2025 | benzinga.com

Rallybio Discontinues Development of Treatment for Prevention of Rare Immune Disorder

April 8, 2025 | marketwatch.com

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

April 8, 2025 | finance.yahoo.com

Rallybio reports Q4 EPS (25c), consensus (30c)

March 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, AFMD, NERV, and RLYB Company Descriptions

Affimed NASDAQ:AFMD

$0.18 -0.10 (-34.95%)

As of 05/19/2025

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Minerva Neurosciences NASDAQ:NERV

$1.82 +0.02 (+1.09%)

Closing price 03:49 PM Eastern

Extended Trading

$1.80 -0.02 (-0.82%)

As of 06:29 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Revelation Biosciences NASDAQ:REVB

$0.84 -0.03 (-3.56%)

Closing price 04:00 PM Eastern

Extended Trading

$0.95 +0.11 (+13.23%)

As of 08:00 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Rallybio NASDAQ:RLYB

$0.35 -0.02 (-5.27%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 +0.01 (+1.85%)

As of 07:55 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time